Clinical trial · Observational
Individualized Surgical Guidance in HCC-BDTT
Individualized Surgical Guidance for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Causal Modeling Study Integrating Preoperative Imaging and Clinical Features
NCT07483242CI-TRIAL-00105973completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Rboost causal model can identify patients who are most likely to benefit among HCC-BDTT patients. Adherence to the individualized recommendation improves survival. This data-driven tool offers vital support for precision surgical decision-making in this high-risk disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bile Duct Resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Bile Duct Resection (BDR) group
- interventionNames
- Procedure: Bile Duct Resection
- label
- Non-Bile Duct Resection (NBDR) group
Primary outcomes (1)
- measure
- Treatment Effects
- timeFrame
- 2025.09.01
- description
- 5-year overall survival (OS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 31 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed HCC with BDTT; * Absence of extrahepatic malignancies at the time of HCC diagnosis; * Undergone R0 curative hepatectomy; * No prior antitumor therapies, such as chemotherapy or immunotherapy, before surgery; * Availability of preoperative imaging (CT or MRI) with standardized tumor evaluation. Exclusion Criteria: * Pathological findings indicating concurrent cholangiocarcinoma and HCC; * Loss to follow-up, preventing outcome evaluation, or insufficient clinical data for analysis. * Significant comorbidities (e.g., severe cardiac or renal failure) that could affect surgical outcomes.
References
Publications (0)
Data not yet available
No reference posted for this study.